Vanda Pharmaceuticals Shareholder Alert: Briscoe Law and Powers Taylor Investigate Possible Breaches

Before you go, we thought you'd like these...
Before you go close icon

Vanda Pharmaceuticals Shareholder Alert: Briscoe Law and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors

DALLAS--(BUSINESS WIRE)-- Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor, LLP announce that a federal class action lawsuit has been filed against Vanda Pharmaceuticals, Inc. ("Vanda" or "Company") (NasdaqGM: VNDA). The firms are investigating additional legal claims against the officers and Board of Directors of Vanda during the period of December 18, 2012 and June 18, 2013 (the "Class Period").

If you are an affected investor and you want to learn more about the lawsuit or join the action, contact Willie Briscoe at The Briscoe Law Firm, PLLC, (214) 239-4568, or via email at, or Zachary Groover at Powers Taylor, LLP, toll free (877) 728-9607, via email at There is no cost or fee to you.

In a recently filed federal class action complaint, Vanda and certain of its officers and directors were charged with violating certain provisions of the Securities Exchange Act of 1934. Specifically, the complaint alleges that among other things, defendants' misrepresented and/or failed to disclose that: (a) Vanda had to change the primary endpoint in the middle of the Phase III studies due to the data suggesting that the original primary endpoint was not going to be met; (b) Vanda eliminated nighttime total sleep as the primary endpoint in its studies as there was no discernible difference in efficacy and safety in nighttime total sleep between those patients deemed to have Non-24 and those patients with a normal circadian rhythm; (c) the replacement primary endpoint installed to assess tasimelteon's efficacy and safety was created ex ante by Vanda and has never been used before in sleep-drug clinical trials, nor was it endorsed by the FDA; and (d) due to the above, Vanda's statements were materially false and misleading at all relevant times. According to the complaint, when doubts regarding the quality and efficacy of Vanda's clinical trial procedure and test data, Vanda shares declined more that 22%.

Shareholder rights attorney Willie Briscoe said, "Recent revelations about alleged improper business practices and procedures regarding key aspects of Vanda's business and other misleading financial statements have prompted the firms to investigate possible breaches of fiduciary duties and other violations of state law by Vanda's officers and directors. Based on our investigation, we are prepared to pursue litigation to preserve the company and the value of Vanda's stock for all shareholders."

The Briscoe Law Firm, PLLC is a full service business litigation, commercial transaction, and public advocacy firm with more than 20 years of experience in complex litigation and transactional matters.

Powers Taylor, LLP is a boutique litigation law firm that handles a variety of complex business litigation matters, including claims of investor and stockholder fraud, shareholder oppression, shareholder derivative suits, and security class actions.

The Briscoe Law Firm, PLLC
Willie Briscoe, 214-239-4568
Powers Taylor, LLP
Zachary Groover, 877-728-9607

KEYWORDS:   United States  North America  Texas


The article Vanda Pharmaceuticals Shareholder Alert: Briscoe Law and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

People are Reading